Abstract
The G2/M checkpoint is an attractive pathway for targeting and sensitizing tumor cells to cancer treatment. Abrogation of the G2/M checkpoint by targeting molecules, such as checkpoint kinase 1 (chk1), increases DNA breakage and sensitizes tumor cells to anti-tumoral agents. However, most of the previously described G2/M abrogators are actually targeting the G2-M border checkpoints rather than mitotic checkpoints. This prompted us to test the effects of combined targeting of chk1 and a critical regulator of mitosis, polo-like kinase 1 (plk1). Chk1 and plk1 were found to be co-expressed in 70% of primary neoplastic tissues we examined. Asynchronized tumor cells were treated with different DNA damaging-agents to activate G1/S, S or G2/M checkpoints. Either chk1 or plk1-specific antisense oligodeoxynucleotides (ASODN) enhanced DNA damaging agent-induced apoptosis. When used in combination, however, chk1- plus plk1-specific ASODN failed to produce synergistic effects. Moreover, selective targeting of plk1 or chk1 in tumor xenografts of mice by oncolytic adenovirus mutants demonstrated potent anti-tumoral efficacy in the presence of low dose cisplatin. Again, combined targeting of chk1 and plk1 did not further enhance anti-tumoral efficacy. We concluded that combined targeting of chk1 and plk1 was not superior to either targeting chk1 or plk1 alone, which suggested that chk1 and plk1 silencing might overlap in their mechanism of action. Whether combined targeting of chk1 with other, more specific mitotic regulators would synergistically sensitize tumor to anti-neoplastic therapeutics needs to be further clarified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sorensen CS, Hansen LT, Dziegielewski J et al (2005) The cell-cycle checkpoint kinase chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7:195–201
Wong CF, Guminski A, Saunders NA, Burgess AJ (2005) Exploiting novel cell cycle targets in the development of anticancer agents. Curr Cancer Drug Targets 5:85–102
Zhou BB, Bartek J (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4:216–225
Yu Q, La RJ, Zhang H et al (2002) UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, chk2 and chk1. Canc Res 62:5743–5748
Kortmansky J, Shah MA, Kaubisch A et al (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875–1884
Blagden S, de Bono J (2005) Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6:325–335
Dai W, Cogswell JP (2003) Polo-like kinases and the microtubule organization center: targets for cancer therapies. Prog Cell Cycle Res 5:327–334
van Vugt MA, Bras A, Medema RH (2004) Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 15:799–811
Reagan-Shaw S, Ahmad N (2005) Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. Faseb J 19:611–613
Gumireddy K, Reddy M, Cosenza S et al (2005) ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7:275–286
Zhou J, Gao Q, Chen G et al (2005) Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 11:8431–8440
Gao Q, Zhou J, Huang X, Fei Y, Lu Y (2006) Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Molecular Therapy in press
Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Molecul Cancer Therap 3:513–519
Anderson H, Andersen R, Roberge M (2003) Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Progr Cell Cycle Res 5:423–430
Shi Z, Azuma A, Sampath D et al (2001) S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Canc Res 61:1065–1072
Ito Y, Nakamura Y, Yoshida H et al (2005) Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features. Pathobiology 72:186–190
Weichert W, Schmidt M, Jacob J et al (2005) Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 55:259–265
van Vugt MA, Medema RH (2005) Getting in and out of mitosis with Polo-like kinase-1. Oncogene 24:2844–2859
Weaver B, Cleveland D (2005) Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7–12
Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5:773–785
Xiao Z, Xue J, Semizarov D et al (2005) Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int J Cancer 115:528–538
Cheung HW, Jin DY, Ling MT et al (2005) Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 65:1450-1458
Dowling M, Voong KR, Kim M et al (2005) Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4:197–206
Lara PN Jr, Mack PC, Synold T et al (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11:4444–4450.
Meng L, Zhou J, Seradr E, Bulun (2001) TNF alpha and IL-11 secreted by malignant breast epithelial cells inhibit adipocytes differentiation by selectively downregulating C/EBP alpha and PPAR gammar: mechanism of desmoplastic reaction. Cancer Res 61:2250
Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE (2001) Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 61:2328–2334
Xu G, Arregui C, Lilien J (2002) PTP1B modulates the association of beta-catenin with N-cadherin through binding to an adjacent and partially overlapping target site. J Biol Chem 277:49989–49997
Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701–1713
Tao D, Wu J, Feng Y et al (2004) New method for the analysis of cell cycle-specific apoptosis. Cytometry A 57:70–74
Heise C, Hermiston T, Johnson L et al (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6:1134–1139
Author information
Authors and Affiliations
Corresponding author
Additional information
Qinglei Gao and Xiaoyuan Huang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Gao, Q., Huang, X., Tang, D. et al. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis 11, 1789–1800 (2006). https://doi.org/10.1007/s10495-006-9421-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-006-9421-4